JP7773991B2 - マスクされたｉｌ１２融合タンパク質及びその使用方法 - Google Patents

マスクされたｉｌ１２融合タンパク質及びその使用方法

Info

Publication number
JP7773991B2
JP7773991B2 JP2022557752A JP2022557752A JP7773991B2 JP 7773991 B2 JP7773991 B2 JP 7773991B2 JP 2022557752 A JP2022557752 A JP 2022557752A JP 2022557752 A JP2022557752 A JP 2022557752A JP 7773991 B2 JP7773991 B2 JP 7773991B2
Authority
JP
Japan
Prior art keywords
polypeptide
masked
fusion protein
amino acid
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518518A5 (enExample
JP2023518518A (ja
Inventor
ライアン ブラックラー，
ゲーザ フォルカース，
デイビッド ドゥーダ，
フォン クロイデンシュタイン， トーマス シュプレーター
ジェネビーブ デジャルダン，
ニコル アファカン，
Original Assignee
ザイムワークス ビーシー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイムワークス ビーシー インコーポレイテッド filed Critical ザイムワークス ビーシー インコーポレイテッド
Publication of JP2023518518A publication Critical patent/JP2023518518A/ja
Publication of JP2023518518A5 publication Critical patent/JP2023518518A5/ja
Application granted granted Critical
Publication of JP7773991B2 publication Critical patent/JP7773991B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022557752A 2020-03-23 2021-03-23 マスクされたｉｌ１２融合タンパク質及びその使用方法 Active JP7773991B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062993334P 2020-03-23 2020-03-23
US62/993,334 2020-03-23
US202163146567P 2021-02-05 2021-02-05
US63/146,567 2021-02-05
PCT/CA2021/050383 WO2021189139A1 (en) 2020-03-23 2021-03-23 Masked il12 fusion proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023518518A JP2023518518A (ja) 2023-05-01
JP2023518518A5 JP2023518518A5 (enExample) 2024-04-01
JP7773991B2 true JP7773991B2 (ja) 2025-11-20

Family

ID=77890776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557752A Active JP7773991B2 (ja) 2020-03-23 2021-03-23 マスクされたｉｌ１２融合タンパク質及びその使用方法

Country Status (10)

Country Link
US (1) US20230122079A1 (enExample)
EP (1) EP4126972A4 (enExample)
JP (1) JP7773991B2 (enExample)
KR (1) KR20230024252A (enExample)
CN (1) CN115529826A (enExample)
AU (1) AU2021240872A1 (enExample)
BR (1) BR112022019020A2 (enExample)
CA (1) CA3147126A1 (enExample)
MX (1) MX2022011676A (enExample)
WO (1) WO2021189139A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CA3178657A1 (en) * 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
US20250051413A1 (en) * 2021-01-12 2025-02-13 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
JP2024535925A (ja) * 2021-09-29 2024-10-02 ザイムワークス ビーシー インコーポレイテッド 修飾されたインターロイキンｐ４０サブユニットタンパク質及びその使用方法
WO2023141601A1 (en) * 2022-01-20 2023-07-27 Repertoire Immune Medicines, Inc. Cd8-targeted il-12 fusion proteins
EP4372000B1 (en) * 2022-02-15 2026-06-17 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
CN120035602A (zh) * 2022-06-17 2025-05-23 辉瑞公司 Il-12变体、抗-pd1抗体、融合蛋白及其用途
WO2024148369A1 (en) * 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
AU2024207005A1 (en) * 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2024153768A1 (en) * 2023-01-20 2024-07-25 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins
TW202517789A (zh) * 2023-07-04 2025-05-01 香港商禮邦醫藥（香港）有限公司 Ｋｌｋ１融合蛋白質的製備方法
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN119823266A (zh) * 2023-10-13 2025-04-15 英脉德医疗科技(广东)有限公司 肿瘤微环境特异激活的cd47抗体
CN122349538A (zh) * 2023-12-07 2026-07-07 上海药明生物技术有限公司 针对il-12受体的异二聚体蛋白
KR20260114559A (ko) * 2023-12-08 2026-07-22 아뮤닉스 파마슈티컬스, 인크. 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN117838836B (zh) * 2024-01-11 2024-06-28 广州医科大学附属第二医院 白介素39在防治血小板减少症中的应用
WO2025160083A1 (en) * 2024-01-22 2025-07-31 Onko-Innate Pty Ltd Targeted low potency il-12 fc fusion proteins and uses thereof
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN110777115A (zh) 2019-11-21 2020-02-11 北京启辰生生物科技有限公司 用于增强抗原递呈细胞致敏t细胞能力的组合物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
IL300408B2 (en) * 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
EP3436477A2 (en) * 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
MX2020014290A (es) * 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CA3126707A1 (en) * 2019-01-29 2020-08-06 Gritstone Bio, Inc. Multispecific binding proteins
WO2021062406A1 (en) * 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
KR20230042315A (ko) * 2020-07-20 2023-03-28 자임워크스 비씨 인코포레이티드 리간드-수용체 쌍 및 생물학적 기능성 단백질을 포함하는 융합 단백질

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN110777115A (zh) 2019-11-21 2020-02-11 北京启辰生生物科技有限公司 用于增强抗原递呈细胞致敏t细胞能力的组合物及应用

Also Published As

Publication number Publication date
WO2021189139A1 (en) 2021-09-30
AU2021240872A1 (en) 2022-11-17
US20230122079A1 (en) 2023-04-20
CA3147126A1 (en) 2021-09-30
KR20230024252A (ko) 2023-02-20
CN115529826A (zh) 2022-12-27
EP4126972A1 (en) 2023-02-08
EP4126972A4 (en) 2024-05-01
JP2023518518A (ja) 2023-05-01
BR112022019020A2 (pt) 2023-02-07
MX2022011676A (es) 2023-03-08

Similar Documents

Publication Publication Date Title
US20230122079A1 (en) Masked il12 fusion proteins and methods of use thereof
JP7846668B2 (ja) リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質
CN115397866B (zh) 靶向dll3的多特异性抗原结合分子及其用途
US20240228567A1 (en) Modified interleukin p40 subunit proteins and methods of use thereof
EP4277922A2 (en) Chimeric molecules comprising il-12 agonist polypeptide
US20230121511A1 (en) Method for producing multispecific antigen-binding molecules
HK40085919A (en) Masked il12 fusion proteins and methods of use thereof
HK40110021A (en) Modified interleukin p40 subunit proteins and methods of use thereof
JP2026505747A (ja) Ｃｓｆ１ｒおよびｃｄ３に結合する抗体
HK40119034A (en) Interferon gamma variants and antigen binding molecules comprising these
CN121127493A (zh) 靶向干扰素 α 融合蛋白及使用方法
CN121487963A (zh) 多特异性蛋白质前药构建体
HK40128956A (en) Pd-1-regulated il-2 immunocytokine and uses thereof
TW202528353A (zh) 與ｆｏｌｒ１結合之抗體及使用方法
HK40091599A (en) Immune activating fc domain binding molecules
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN119095880A (zh) 干扰素γ变体以及包含这些变体的抗原结合分子
HK40094278A (en) Fusion proteins comprising a ligand-receptor pair and a biologically functional protein
HK40076462B (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251110

R150 Certificate of patent or registration of utility model

Ref document number: 7773991

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150